Aytu BioPharma, Inc. reported a significant decline in financial performance for the three and nine months ended March 31, 2026, as detailed in its latest 10-Q filing. The company recorded net revenues of $12.4 million for the third quarter, a decrease of 33% from $18.5 million in the same period last year. For the nine-month period, revenues fell to $41.5 million from $51.2 million, marking a 19% decline. The gross profit also decreased, totaling $7.6 million for the quarter, down from $12.8 million, while the nine-month gross profit dropped to $26.4 million from $35.6 million. The company reported a net loss of $5.6 million for the quarter, compared to a net income of $4.0 million in the prior year, and a net loss of $14.2 million for the nine months, contrasting with a net income of $6.3 million in the same period last year.
The decline in revenue is attributed to a strategic shift in marketing focus towards the recently launched EXXUA, a treatment for major depressive disorder (MDD), which has become the centerpiece of Aytu's commercial efforts. The ADHD product portfolio saw a notable decrease in revenue, primarily due to the launch of a generic version of one of its ADHD products and a broader deemphasis in marketing. The Pediatric Portfolio also faced challenges, with increased returns and higher rebates impacting sales. Despite these challenges, the successful launch of EXXUA contributed $2.4 million in revenue during the quarter.
In terms of operational changes, Aytu has suspended active development of its clinical programs to concentrate on commercializing its existing products. The company has also divested its Consumer Health business, which was completed in July 2024, and now operates as a single reporting segment. Aytu has entered into exclusive commercialization agreements for its ADHD products in international markets, including agreements with Medomie Pharma in Israel and Lupin Pharma in Canada, which are expected to enhance its market presence.
Financially, Aytu's total assets decreased to $111.7 million as of March 31, 2026, down from $124.2 million at the end of the previous fiscal year. The company reported current liabilities of $60.0 million, a slight decrease from $63.1 million, while total stockholders' equity increased to $35.1 million from $19.0 million, reflecting a capital raise through the issuance of common stock and warrants. The company’s cash and cash equivalents stood at $26.7 million, down from $30.9 million, indicating a need for careful cash management moving forward.
Looking ahead, Aytu BioPharma aims to leverage the launch of EXXUA to drive growth and improve its financial position. The company is focused on achieving positive operating cash flows and plans to continue evaluating strategic partnerships and collaborations to enhance shareholder value. However, it remains cautious of external market conditions, including inflationary pressures and potential supply chain disruptions, which could impact its operations and financial performance in the near term.
About AYTU BIOPHARMA, INC
Aytu BioPharma, Inc. is a pharmaceutical company specializing in innovative treatments for central nervous system disorders, primarily major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Its core products include EXXUA, a novel selective serotonin 5HT1a receptor agonist for MDD, and extended-release orally disintegrating tablets Adzenys and Cotempla for ADHD. The company also offers pediatric allergy and fluoride supplement products, marketing primarily in the U.S. through third-party wholesalers and an internal sales force.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.